The Illinois medical licensing board filed a request to revoke the license of a Chicago physician accused of leaving patients with deformed penises, according to a report by United Press International (UPI).
Endoscopic injection of hyaluronic acid/dextranomer (NASHA/Dx) gel can be considered as a first-line option for vesicoureteral reflux (VUR) in children, researchers say.
Renal hypertrophy is a major factor in the development of diabetic nephropathy in patients with type 1 diabetes.
The FDA has issued interim recommendations for using Trasylol (aprotinin injection) until a study determines if the drug increases the likelihood of death, serious kidney damage, congestive heart failure, and strokes.
Merck and Schering-Plough Pharmaceuticals have received approval to include new data in their label for Vytorin (ezetimibe/simvastatin), which the two companies co-market.
Uroplasty, Inc., of Minnetonka, Minn., announced that it has received an approvable letter from the FDA following the agency’s scientific review of the safety and efficacy of Macroplastique Implants for female stress urinary incontinence.
Wyeth Pharmaceuticals has submitted a New Drug Application (NDA) for Torisel (temsirolimus) for treating advanced renal cell carcinoma.
Medwave Inc., of Danvers, Mass., has received clearance to market Fusion, the first completely sensor-based monitor to evaluate BP and vital signs.
IN THE United States, the incidence of urinary stone disease is about 12% in men and 7% in women, and evidence suggests that these numbers are increasing. For patients who form stones, the likelihood of a recurrence is nearly 50% within five years and up to 95% over a lifetime.
Under a new Florida Medical Association (FMA) program, physicians may start asking patients to sign documents limiting the amount of money they could seek in malpractice lawsuits.
